• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

AMA: Serological Tests for SARS-CoV-2 Antibodies Should Not Be Offered to Individuals

Article

Doctors group says tests should be reserved for population-level studies and few other circumstances.

Citing concerns about false positives, cross reactivity and uncertainty about the immune response to the virus, the AMA says serologic tests for the antibodies to SARS-CoV-2, the virus that causes COVID-19, should not be offered to individuals.

People who test positive for the protective antibodies may “falsely assume it is safe to discontinue physical distancing,” the AMA says in a statement issued yesterday. The physician’s organization also said that there is growing concern about poor test performance and fraudulent claims. And it cast doubt on the rigor of FDA approval process:  “The FDA does not automatically independently verify performance of each of these tests and primarily relies on submitting manufacturers to self-validate their offerings.”

Serological tests should currently be used only in population studies, for evaluation of people who have recovered from COVID-19 who might be donating convalescent plasma, and in circumstances that are part of testing plan and “in concert with other clinical information,”
says the statement.

The AMA does not point to a specific false positive rate for the current crop of SARS-CoV-2 antibody tests. Rather, it makes a general point that even tests with high sensitivity and specificity will have false positives if the disease has a low prevalence “as is currently the case for COVID-19.”

While cross reactivity - a different infection, possibly with another type of coronavirus, producing antibodies that a serological test recognizes as being the same as those triggered by SARS-CoV-2 - has been a concern with some of current tests for SARS-CoV-2 antibodies. “For tests where cross-reactivity is possible, antibodies for other coronaviruses may result in a positive test result for SARS-CoV-2 even when the patient in question was not infected,” the AMA says.

The organization’s statement also mentions the uncertainty about the immune response to SARS-CoV-2. “It not yet clear when an immune response develops after COVID-19 infection, how strong this immune response may be, and how long the immune response may last,” says the statement. 

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.